Vitaspring Biomedical CO LTD 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
VitaSpring Biomedical Co., Ltd. filed its annual report, highlighting substantial doubt about its ability to continue as a going concern due to a lack of revenue and significant liabilities.
OTC.Pink
VitaSpring Biomedical Co., Ltd. has filed its delayed Form 10-K for the fiscal year ended January 31, 2025, detailing its development-stage status, ongoing financial challenges, and strategic focus on regenerative medicine.
OTC.Pink
VitaSpring Biomedical Co. Ltd. reported no revenue for fiscal year 2024, a net loss of $1.1 million, and a substantial accumulated deficit, raising significant doubt about its ability to continue as a going concern.
OTC.Pink
VitaSpring Biomedical Co. Ltd. reported a net loss of $4.16 million for the fiscal year ended January 31, 2023, a significant decline from the prior year's profit, as it focuses on R&D and seeks additional capital.